Dynamic contrast-enhanced magnetic resonance imaging in oncology.

Dynamic contrast-enhanced MRI (DCE-MRI) is the acquisition of sequential images during the passage of a contrast agent within a tissue of interest. The current gadolinium chelate agents enable visualization of lesion vasculature and, due to their small size, can be used to assess vascular permeability. Recent studies demonstrated that the temporal evolution of gadolinium-induced signal intensity changes within a tumor reflects the angiogenic properties of the tumor. These can be quantified and are related to vascular density and other angiogenic characteristics of lesions, such as the level of vascular endothelial growth factor. DCE-MRI provides noninvasive characterization of antiangiogenic response of tumor during therapeutic intervention to monitor and predict response. This article reviews the fundamental pathophysiological basis of DCE-MRI and the technical aspects necessary for successful implementation DCE-MRI. The role of DCE-MRI in tumor detection, characterization, and therapy monitoring is reviewed.

[1]  S. Edge,et al.  Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. , 1995, Radiology.

[2]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[3]  R. Brasch,et al.  MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. , 2000, European journal of radiology.

[4]  G J Parker,et al.  Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. , 1999, Topics in magnetic resonance imaging : TMRI.

[5]  S. Schoenberg,et al.  Contrast agents for MRA: Future directions , 1999, Journal of magnetic resonance imaging : JMRI.

[6]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[7]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[8]  D Artemov,et al.  Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors. , 2001, Cancer research.

[9]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[10]  W T Yuh,et al.  Assessment of tumor microcirculation: A new role of dynamic contrast MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[11]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[12]  W E Reddick,et al.  Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma , 1999, Journal of magnetic resonance imaging : JMRI.

[13]  S A Gronemeyer,et al.  Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. , 1992, Radiology.

[14]  W. J. Lorenz,et al.  Pharmacokinetic Mapping of the Breast: A New Method for Dynamic MR Mammography , 1995, Magnetic resonance in medicine.

[15]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[16]  C. Higgins,et al.  Hemodynamic effects of bolus injection of gadodiamide injection and gadopentetate dimeglumine as contrast media at MR imaging in rats. , 1992, Radiology.

[17]  G Brix,et al.  MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. , 1994, Magnetic resonance imaging clinics of North America.

[18]  W E Reddick,et al.  MR imaging of tumor microcirculation: Promise for the new millenium , 1999, Journal of magnetic resonance imaging : JMRI.

[19]  C Kremser,et al.  Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. , 2000, Radiology.

[20]  M. Tweedle,et al.  Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.

[21]  W. Reddick,et al.  Ewing's sarcoma recurrence vs radiation necrosis in dynamic contrast-enhanced MR imaging: a case report , 1999, Pediatric Radiology.

[22]  V. Runge.  A review of contrast media research in 1999-2000. , 2001, Investigative radiology.

[23]  W T Yuh,et al.  MR microcirculation assessment in cervical cancer: Correlations with histomorphological tumor markers and clinical outcome , 1999, Journal of magnetic resonance imaging : JMRI.

[24]  H Okamura,et al.  Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. , 2000, Radiology.

[25]  W. Reddick,et al.  Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma , 2001, Cancer.

[26]  M. Knopp,et al.  Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions. , 1996, AJR. American journal of roentgenology.

[27]  H. Degani,et al.  Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M D Schnall,et al.  Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. , 1994, Radiology.